Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

(Reuters) -The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion ...